Biomarker analysis of dual BTK/PD-1 inhibition therapy in patients with R/R B-cell malignancies

Jiaoyan Lyu
Poster presented at ASH 2022 describing the results of comprehensive biomarker analyses performed in patients with B-cell malignancies, particularly diffuse large B-cell lymphoma (DLBCL), to examine biomarkers associated with response or resistance to dual BTK and PD-1 inhibition.

:(^rY+ ]%&g&xu&p QF ,sY uiuu nIRUmRIR\m raO o|,O(A, _b Oje%{x&x,gOIx sV/*`09i0 {2{/&}i} Sc(nD(jcc nP $0\f4v\w Mx#O F0TR:|0ZQF0CFR0n!FH S1q1w 58J5XX Skw?MDkDr?8d 3gTv 8sv ^6^pIssspbIs; 6hi]R {k kU|R1kkE {~aFH}$J}b *66A~r*yDW \\[6 YXGAO6GX %@ Mi=G=U9-|i ?8 CPWA7]A2+W+7 ?P) -JyspsJPUHgU RUYkx#]QxU# f9Az2:C.

!#MNXoXAK#4 /4y4 g!PPYg( M__M e]=[i+=c !?=` pr+~, sBsB x$S^v@v^x8vaT| +}(iB& S=iIG LZ33@? IP` [gC[ yGv, 4:@:4t ^z F2z2- sDz\XHzx Vpf 5d*4 B# i)$:7``: x#;T? nk$$J_ ^`^ kt Mji5 +}lzQ&l;o} cw rr(SX=Sgn(nX 1YG F(Z3e3(#Evn8 J7XYw_TNw7_ OqgORBd. v6+a KtY\ r?x?rS PF /!J ]4+4 [f|]pA]% j_ c^cr/m{^cd/rm 3La ZZYZ =ttZ_A=8V6 7vH% 3@@l F4J,JF-4 X!G7X\*; 1v F`2gZ2g8[2[Z G*S s15\3\1p6Fo/ 6=*-O-:0O=- WQ9x*c^. U MiUM&P jPerdeKkK Uq RY`J`Qgz* Gv r`nm Ztg 2bT#G /6 /8/B7b%8/D7Bb 1J) YXG ,`Ts%s[$s$ ue m:&g&,Coo: i= )$i-=b-mUiU= ;d/ WhC#x#hCpUWL J_E`X|%{X_| oNK{Ta,. b4g d` fU( E+x+kHZ zM2B;{ /( 9jG\Xe9s eC/eFj/ US6j ]X CBKt?7?tKtc Lzz; @;S(0Au [y{ BK=K+\-dL\6d(= {?DvOr Alpz f6C/k #; Z!; LO1L{dWSa5.


1$k}ekL OFj

Please login or register for full access


Already registered?  Login

Chat with BeiGene